Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Status:
Suspended
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
This is an open-label, Phase I/Ib trial with a dose escalation phase, followed by a dose
extension phase. The objective of the dose escalation phase is to evaluate the
pharmacokinetics (PK) and MTD of P1446A-05 in relapsed/refractory CLL and the objective of
the dose extension phase is to evaluate the safety, efficacy and pharmacodynamics of
P1446A-05 in 14 patients at the MTD level.
Phase:
Phase 1
Details
Lead Sponsor:
Piramal Enterprises Limited
Collaborators:
Dana-Farber Cancer Institute Norris Cotton Cancer Center